Bruno Cappelozza, a former PFL heavyweight champion, has accepted a one-year suspension from USADA following a second drug test failure.
Cappelozza (15-7, 1NC) was the 2021 PFL heavyweight tournament winner, but was forced out of the season due to injury the following year. In 2023, he was one of several PFL athletes who failed drug tests during an April stint in Las Vegas, forcing the PFL to engage USADA to handle out of competition drug testing for the league.
While the April 2023 failure by Cappelozza was for Drostanolone and fell under the Nevada State Athletic Commission, earlier this year, the Brazilian failed another test. This time, Cappelozza tested positive for clomiphene and its metabolite desethyl-clomifene in an out-of-competition drug test, with his sample collected April 17, 2024.
That drug test was administered by USADA.
Clomiphene is prohibited at all times under the PFL Anti-Doping Policy and PFL Prohibited List. Cappelozza’s one-year suspension has been backdated to April 17 and is the maximum penalty for the offense.
Bruno Cappelozza last fought in February, when he was submitted by Vadim Nemkov as part of the PFL Champions vs. Bellator Champions card. That remains his only fight since 2022, and this latest suspension means he will have missed two consecutive PFL seasons, outside of his lone 2023 fight against Matheus Scheffel, which was overturned to a No Contest.
